Identification of a novel mutation of rare CLN6 case and computation protein structure
Abstract
Neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, jointly account for the highest incidences of hereditary neurodegenerative disease in childhood. This disease is mainly presented by vision loss, ataxia, premature mortality in later stages, and epileptic seizures. NCLs are categorized into different types that rely on deficiencies in several genes. CLN6 is one of the identified NCLs, and a mutated gene affects a transmembrane protein embedded in the Endoplasmic Reticulum (RM). Here, we report two cases presenting clinical features of CLN6. A homozygous novel mutation NM_017882.2: Exon 7: c.268A>G (p.Asn90Asp) as well as another homozygous mutation in NM_017882.2: Exon 3: c.679G<A. Following the finding of novel mutation, the Sanger sequencing method was employed to confirm the outcome. Also, we performed a 3D structure prediction for the CLN6 protein. InterPro was taken advantage to assess the domains and function in mutated sites. Both mutations are located in the extracellular domain of the CLN6 protein.
Downloads
References
2. Tuermer A, Mausbach S, Kaade E, Damme M, Sylvester M, Gieselmann V, et al. CLN6 deficiency causes selective changes in the lysosomal protein composition. Proteomics. 2021; 21(19): 2100043.
3. Bajaj L, Sharma J, di Ronza A, Zhang P, Eblimit A, Pal R, et al. A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J Clin Investig. 2020; 130(8): 4118-4132.
4. Nicolaou P, Tanteles GA, Votsi C, Zamba-Papanicolaou E, Papacostas SS, Christodoulou K, et al. A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature. Front Genet. 2021; 12: 746101-746101.
5. Nosková L, Stránecký V, Hartmannová H, Přistoupilová A, Barešová V, Ivánek R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Human Gen. 2011; 89(2): 241-252.
6. Sims KB, Cole AJ, Sherman JC, Caruso PA, Snuderl M. Case 8-2011: a 32-year-old woman with seizures and cognitive decline. New Engl J Med. 2011; 364(11): 1062-1074.
7. Gao H, Boustany R-MN, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, et al. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Human Gen. 2002; 70(2): 324-335.
8. Shiro Y, Yamashita A, Watanabe K, Yamazaki T. CLN6’s luminal tail-mediated functional interference between CLN6 mutants as a novel pathomechanism for the neuronal ceroid lipofuscinoses. Biomed Res. 2021; 42(4): 129-138.
9. Best HL, Clare AJ, McDonald KO, Wicky HE, Hughes SM. An altered secretome is an early marker of the pathogenesis of CLN6 Batten disease. J Neurochem. 2021; 157(3): 764-780.
10. Lu G, Moriyama EN. Vector NTI, a balanced all-in-one sequence analysis suite. Briefings Bioinf. 2004; 5(4): 378-388.
11. Wei G-W. Protein structure prediction beyond AlphaFold. Nature Machine Intellig. 2019; 1(8): 336-337.
12. Mulder N, Apweiler R. Interpro and interproscan. Comparative genomics, Springer: 2007; 59-70.
13. Nicolaou P, Tanteles GA, Votsi C, Zamba-Papanicolaou E, Papacostas SS, Christodoulou K, et al. A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature. Front Genet. 2021; 12.
14. Tuermer A, Mausbach S, Kaade E, Damme M, Sylvester M, Gieselmann V, Thelen M. CLN6 deficiency causes selective changes in the lysosomal protein composition. Proteomics. 2021; 21(19): 2100043.
15. Cooper JD. Moving towards therapies for juvenile Batten disease?" Exp Neurol. 2008; 211(2): 329-331.
16. Specchio N, Ferretti A, Trivisano M, Pietrafusa N, Pepi C, Calabrese C, et al. Neuronal ceroid lipofuscinosis: potential for targeted therapy. Drugs. 2021; 81: 101-123.
17. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009; 25(9): 1189-1191.
18. Liu W, Herranz-Martin S, Aristorena M, Mole SE, Smith AJ, Ali RR, Rahim AA. Experimental gene therapies for the NCLs. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(9): 165772.
This work is licensed under a Creative Commons Attribution 4.0 International License.